Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

  • 25 mg - 25 EUR
  • 100 mg - 75 EUR
  • 250 mg - 150 EUR

Imatinib mesylate

Imatinib is an inhibitor of several tyrosine kinases that is selective for the oncoproteins BCR/Abl, c-Kit and PDGFR. It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and some other diseases in which these kinases are strongly expressed or unusually active. As one of the first cancer drugs developed using the principles of rational drug design based on an understanding of how cancer cells work, Imatinib is a ground-breaking compound. It was approved in the U.S. in 2001 for the treatment of Philadelphia-chromosome positive (Ph+) CML and in 2002 for the treatment of patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

catalogue number: I040
synonyms: Gleevec, Glivec, STI571
CAS: 220127-57-1
MW: 589.7 g/mol

Nat Rev Drug Discov. 2002 Jul;1(7):493-502. PMID: 12120256

  • 5 mg - 80 EUR
  • 25 mg - 320 EUR
  • 100 mg - 960 EUR


Intedanib is a kinase inhibitor blocking VEGFR, PDGFR and FGFR receptors, developed for the treatment of several malignancies and idiopathic pulmonary fibrosis. Intedanib also significantly decreased blood vessel area in treated tumours. The sustained inhibition of VEGFR phosphorylation, the fast in vivo clearance and clinical efficacy against a broad range of malignancies appear to be the major advantages of intedanib. Furthermore, the existing data suggest an excellent safety profile. As of 2012, intedanib undergoes several phase III trials for the treatment of NSCLC and ovarian cancer.

catalogue number: I144
synonyms: BIBF1120, Nintedanib, Vargatef
CAS: 656247-17-5
MW: 539.62 g/mol

J Med Chem. 2009 Jul 23;52(14):4466-80. PMID: 19522465
IDrugs. 2010 May;13(5):332-45. PMID: 20432191

  • 5 mg - 41 EUR
  • 25 mg - 164 EUR
  • 100 mg - 492 EUR


Indirubin is an inhibitor of cyclin-dependent kinases and GSK3b inhibitor, with IC50 values against the two kinase classes of approximately 75 nM and 190 nM, respectively. Indirubin was identified as the active ingredient of Danggui Longhui Wan, a mixture of plants that is used in traditional Chinese medicine to treat chronic diseases.

catalogue number: I041
CAS: 479-41-4
MW: 262.26 g/mol

Nat Cell Biol. 1999 May;1(1):60-7. PMID: 10559866

  • 5 mg - 98 EUR
  • 25 mg - 392 EUR
  • 100 mg - 1176 EUR


Indirubin-3'-monooxime is an inhibitor of GSK3b (IC50=22 nM), CDK1 (IC50=180 nM) and CDK5 (IC50=100 nM). Treatment with indirubin-3-monooxime caused time-dependent inhibition of cell growth, with the treated cells exhibiting many hallmark features of apoptosis.

catalogue number: I042
CAS: 160807-49-8
MW: 277.3 g/mol

Biomed Pharmacother. 2009 Feb;63(2):146-54. PMID: 18450412

  • 5 mg - 98 EUR
  • 25 mg - 392 EUR
  • 100 mg - 1176 EUR

Indirubin-5-sulfonic acid

Indirubin-5-sulfonic acid is an indigoid inhibitor of CDK1/cyclin B (IC50= 55nM), CDK2/cyclin A (IC50=35 nM), CDK2/cyclin E (IC50=150 nM), CDK4/cyclin D1 (IC50=300 nM), CDK5/p35 (IC50=65 nM) and GSK3b (IC50=280 nM).

catalogue number: I043
CAS: 864131-82-8
MW: 342.33 g/mol

Structure. 2001 May 9;9(5):389-97. PMID: 11377199
Eur J Biochem. 2004 Jun;271(11):2280-90. PMID: 15153119

  • 25 mg - 34 EUR
  • 100 mg - 103 EUR
  • 250 mg - 206 EUR


Irinotecan is a semisynthetic analogue of the natural alkaloid camptothecin. Hydrolysis results in its conversion to SN-38, an inhibitor of topoisomerase I. Inhibition of topoisomerase I by the active metabolite SN-38 prevents DNA replication and transcription. Irinotecan is a second line chemotherapy for advanced colorectal cancer that is used if first-line treatments with oxaliplatin and 5-fluorouracil fail.

catalogue number: I125
synonyms: CPT-11, Camptosar, Campto
CAS: 97682-44-5
MW: 586.68 g/mol

World J Gastroenterol. 2009 Aug 7;15(29):3597-602. PMID: 19653336